Data updated: Jun 28, 2026
Age-Related Macular Degeneration Clinical Trial Landscape
Age-Related Macular Degeneration is being studied across 548 clinical trials registered since 2008, with 138 programs currently active. The competitive pipeline includes 40 active Phase 3 trials, 63 active Phase 2 trials, and 23 active Phase 1 trials.
Top industry sponsors include Roche, AbbVie, EyeBiotech Ltd..
Trial activity
138 active / 548 total since 2008
Active by phase 40 Ph3 / 131 63 Ph2 / 236 23 Ph1 / 99 12 Ph4 / 82
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Roche 9 9 3
AbbVie 6 10 2
EyeBiotech Ltd. 4 1 0
Adverum Biotechnologies, Inc. 4 1 0
Chengdu Origen Biotechnology Co., Ltd. 4 0 0
Ocular Therapeutix, Inc. 3 2 0
4D Molecular Therapeutics 3 0 0
Innostellar Biotherapeutics Co.,Ltd 3 0 0
Novartis 2 34 6
Regeneron 2 7 1
Astellas 2 2 1
EyePoint Pharmaceuticals, Inc. 2 2 0
Alkeus Pharmaceuticals, Inc. 2 2 0
AiViva BioPharma, Inc. 2 1 0
Beijing Anlong Biopharmaceutical Co., Ltd. 2 0 0
How the field has grown
New-trial starts peaked in 2025 (39 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (93 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 14
2017 19
2018 30
2019 31
2020 35
2021 36
2022 33
2023 34
2024 31
2025 39
2026 28
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (0) 0
2017 (2) 37
2018 (9) 535
2019 (12) 382
2020 (12) 449
2021 (12) 468
2022 (10) 428
2023 (4) 387
2024 (12) 400
2025 (10) 356
2026 (10) 344
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT07007065 RECRUITING
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie n=561
NCT06541704 RECRUITING
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals n=975
NCT04657289 ACTIVE NOT RECRUITING
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Hoffmann-La Roche n=451
NCT06668064 ACTIVE NOT RECRUITING
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
EyePoint Pharmaceuticals, Inc. n=400
NCT07440225 RECRUITING
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
EyeBiotech Ltd. n=960
NCT07496567 RECRUITING
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd. n=960
NCT06683742 ACTIVE NOT RECRUITING
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
EyePoint Pharmaceuticals, Inc. n=400
NCT05562947 RECRUITING
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Hoffmann-La Roche n=68
NCT06556368 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
Kodiak Sciences Inc n=675
NCT07482176 RECRUITING
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc. n=284
NCT04704921 ACTIVE NOT RECRUITING
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
AbbVie n=671
NCT06847542 RECRUITING
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Hoffmann-La Roche n=250
NCT03683251 RECRUITING
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Hoffmann-La Roche n=1,000
NCT05112861 ACTIVE NOT RECRUITING
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics, Inc. n=120
NCT05407636 RECRUITING
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
AbbVie n=714
NCT07064759 RECRUITING
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics n=480
NCT07520318 NOT YET RECRUITING
This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.
Shenzhen Oculgen Biomedical Technology Co., Ltd. n=255
NCT07269769 NOT YET RECRUITING
A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD
Tasly Pharmaceutical Group Co., Ltd n=450
NCT07516132 NOT YET RECRUITING
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Ocular Therapeutix, Inc. n=850
NCT06864988 ACTIVE NOT RECRUITING
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics n=480
NCT07489586 NOT YET RECRUITING
A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
Qilu Pharmaceutical Co., Ltd. n=356
NCT07461441 RECRUITING
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
Yeungnam University College of Medicine n=50
NCT07317934 RECRUITING
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Innostellar Biotherapeutics Co.,Ltd n=332
NCT04663750 RECRUITING
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
King's College Hospital NHS Trust n=210
NCT05904028 RECRUITING
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Jaeb Center for Health Research n=600
NCT06952452 RECRUITING
Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
Parc de Salut Mar n=630
NCT06856577 ACTIVE NOT RECRUITING
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Adverum Biotechnologies, Inc. n=311
NCT06373731 ACTIVE NOT RECRUITING
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Stealth BioTherapeutics Inc. n=313
NCT06491914 ACTIVE NOT RECRUITING
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals n=1,118
NCT07189169 RECRUITING
QA108 Phase III Study in Subjects With Intermediate AMD
Smilebiotek Zhuhai Limited n=400
NCT07129239 NOT YET RECRUITING
High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)
Clinique de Retine de l'est n=180
NCT06495918 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
Ocular Therapeutix, Inc. n=825
NCT06305416 RECRUITING
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Incepta Pharmaceuticals Ltd n=70
NCT06223958 ACTIVE NOT RECRUITING
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. n=344
NCT06470373 NOT YET RECRUITING
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
Rophibio, Inc. n=434
NCT05972473 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
Innovent Biologics (Suzhou) Co. Ltd. n=600
NCT05461339 ACTIVE NOT RECRUITING
TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
BioDlink Biopharm Co., Ltd. n=488
NCT06165068 RECRUITING
Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study
Navamindradhiraj University n=174
NCT05251636 NOT YET RECRUITING
Adjunct Episcleral Brachytherapy for PCV
Salutaris Medical Devices, Inc. n=159
NCT07614776 RECRUITING
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen n=304
NCT05536297 COMPLETED
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Astellas Pharma Global Development, Inc. n=278
NCT07389577 COMPLETED
A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)
Jecho Biopharmaceuticals Co., Ltd. n=443
NCT04690556 COMPLETED
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
Lupin Ltd. n=600
NCT07214740 COMPLETED
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
Apellis Pharmaceuticals, Inc. n=44
NCT05439629 COMPLETED
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
Bio-Thera Solutions n=488
NCT04522167 COMPLETED
Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration
Bioeq GmbH n=434
NCT03845582 COMPLETED
Phase 2/3 Study of ALK-001 in Geographic Atrophy
Alkeus Pharmaceuticals, Inc. n=200
NCT04770545 COMPLETED
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Apellis Pharmaceuticals, Inc. n=792
NCT04777201 COMPLETED
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche n=1,036
NCT04435366 COMPLETED
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
IVERIC bio, Inc. n=448
NCT04270747 COMPLETED
A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]
Amgen n=576
NCT04423718 COMPLETED
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
Bayer n=1,011
NCT02243878 COMPLETED
Stereotactic Radiotherapy for Wet AMD (STAR)
King's College Hospital NHS Trust n=411
NCT04757636 TERMINATED
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)
Opthea Limited n=998
NCT03823287 COMPLETED
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
Hoffmann-La Roche n=671
NCT04757610 TERMINATED
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Opthea Limited n=986
NCT03823300 COMPLETED
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
Hoffmann-La Roche n=658
NCT02686658 COMPLETED
Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
IVERIC bio, Inc. n=286
NCT05989126 COMPLETED
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals n=35
NCT05604989 COMPLETED
Associations Between the Oral and Intestinal Microbiome and Neovascular Age-related Macular Degeneration
Seoul National University Bundang Hospital n=45
NCT05003245 COMPLETED
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
Shanghai Henlius Biotech n=407
NCT03844074 COMPLETED
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics, Inc. n=61
NCT03834753 COMPLETED
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics, Inc. n=228
NCT04516278 COMPLETED
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics, Inc. n=195
NCT06190093 COMPLETED
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)
Outlook Therapeutics, Inc. n=400
NCT02307682 COMPLETED
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
Alcon Research n=1,775
NCT02434328 COMPLETED
Efficacy and Safety of RTH258 Versus Aflibercept - Study 2
Alcon Research n=1,048
NCT04740671 COMPLETED
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
Shanghai Henlius Biotech n=410
NCT04047472 COMPLETED
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration
Novartis Pharmaceuticals n=397
NCT04264819 COMPLETED
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals n=295
NCT01940887 TERMINATED
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
Ophthotech Corporation n=645
NCT01944839 TERMINATED
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Ophthotech Corporation n=619
NCT01940900 TERMINATED
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Ophthotech Corporation n=627
NCT04597632 COMPLETED
An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study
Novartis Pharmaceuticals n=248
NCT04239027 COMPLETED
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
Novartis Pharmaceuticals n=210
NCT04005352 COMPLETED
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
Novartis Pharmaceuticals n=734
NCT05155293 COMPLETED
Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
Alvotech Swiss AG n=413
NCT04049266 TERMINATED
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Kodiak Sciences Inc n=559
NCT04964089 COMPLETED
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Kodiak Sciences Inc n=557
NCT04864834 COMPLETED
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration
Sandoz n=485
NCT04450329 COMPLETED
A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Samsung Bioepis Co., Ltd. n=449
NCT05126966 WITHDRAWN
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche
NCT03805100 COMPLETED
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
Xbrane Biopharma AB n=582
NCT04480463 COMPLETED
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Sam Chun Dang Pharm. Co. Ltd. n=576
NCT05569148 COMPLETED
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
Hoffmann-La Roche n=35
NCT05282004 COMPLETED
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
Sandoz n=36
NCT01436864 COMPLETED
A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD
Chengdu Kanghong Biotech Co., Ltd. n=125
NCT05587062 COMPLETED
Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Cinnagen n=168
NCT03710564 TERMINATED
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
Novartis Pharmaceuticals n=535
NCT04636853 COMPLETED
CB-PRP in Retinitis Pigmentosa and Dry Age-related Macular Degeneration
Fondazione Policlinico Universitario Agostino Gemelli IRCCS n=20
NCT02157077 COMPLETED
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Centre Hospitalier Intercommunal Creteil n=90
NCT05161806 COMPLETED
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
Sandoz n=30
NCT03677934 COMPLETED
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
Hoffmann-La Roche n=415
NCT05345236 COMPLETED
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
Qilu Pharmaceutical Co., Ltd. n=366
NCT02611778 COMPLETED
Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
Bioeq GmbH n=712
NCT04697953 WITHDRAWN
Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)
Novartis Pharmaceuticals
NCT03577899 TERMINATED
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
Chengdu Kanghong Biotech Co., Ltd. n=1,157
NCT03630952 TERMINATED
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
Chengdu Kanghong Biotech Co., Ltd. n=1,157
NCT02540954 COMPLETED
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Bayer n=336
NCT03150589 COMPLETED
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Samsung Bioepis Co., Ltd. n=705
NCT04857177 COMPLETED
A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
Chong Kun Dang Pharmaceutical n=312
NCT03954626 COMPLETED
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
Novartis Pharmaceuticals n=14
NCT03386474 COMPLETED
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
Novartis Pharmaceuticals n=151
NCT03930641 COMPLETED
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
Novartis Pharmaceuticals n=34
NCT03668054 COMPLETED
Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)
Laboratorio Elea Phoenix S.A. n=22
NCT02032173 TERMINATED
Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
Novartis Pharmaceuticals n=31
NCT00764738 COMPLETED
Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
Retina Macula Institute n=91
NCT02462486 COMPLETED
Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Allergan n=949
NCT02462928 COMPLETED
A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
Allergan n=939
NCT01835067 COMPLETED
Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
King's College Hospital NHS Trust n=55
NCT03034772 COMPLETED
Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration
Wills Eye n=52
NCT01402544 TERMINATED
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
University of California, San Diego n=20
NCT01748292 COMPLETED
Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Charles C Wykoff, PhD, MD n=60
NCT00593450 COMPLETED
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
University of Pennsylvania n=1,208
NCT01780935 COMPLETED
Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals n=671
NCT01948830 COMPLETED
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
Novartis Pharmaceuticals n=650
NCT00826371 COMPLETED
Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients
Novartis Pharmaceuticals n=114
NCT01482910 COMPLETED
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
Bayer n=304
NCT00964795 COMPLETED
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
Regeneron Pharmaceuticals n=323
NCT00557791 WITHDRAWN
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
OPKO Health, Inc.
NCT02035722 COMPLETED
Intravitreal Injections-related Anxiety
University Health Network, Toronto n=73
NCT00637377 COMPLETED
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
Bayer n=1,240
NCT00769015 COMPLETED
Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Thomas Jefferson University n=188
NCT01601483 TERMINATED
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
MacuCLEAR, Inc. n=22
NCT01269697 COMPLETED
Lutein Influence on Macula of Persons Issued From Amd Parents
University Hospital, Bordeaux n=120
NCT00891735 COMPLETED
A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
Genentech, Inc. n=1,097
NCT00599222 COMPLETED
The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study
Anders Kvanta n=100
NCT01327222 COMPLETED
Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)
IRCCS San Raffaele n=20
NCT00709449 COMPLETED
An Open Study Comparing the Effects of Moxaverine on Ocular Blood Flow in Patients With Age- Related Macular Degeneration, Primary Open Angle Glaucoma and Healthy Control Subjects
Medical University of Vienna n=60
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only